A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings

被引：0
|
作者：
Jonker, D. J.
Rosen, L. S.
Sawyer, M.
Wilding, G.
Noberasco, C.
Jayson, G.
Rustin, G.
McArthur, G.
Velasquez, L.
Galbraith, S.
机构：
[1] Ottawa Reg Canc Ctr, Ottawa, ON, Canada
[2] Premiere Oncol, Santa Monica, CA USA
[3] Cross Canc Inst, Edmonton, AB, Canada
[4] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[5] Ist Europeo Oncol, Milan, Italy
[6] Christie Hosp, Manchester, Lancs, England
[7] Mt Vernon Canc Ctr, Northwood, Middx, England
[8] Peter MacCallum Canc Ctr, East Melbourne, Australia
[9] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors
    Banerji, U.
    van Doorn, L.
    Papadatos-Pastos, D.
    Debnam, P.
    Tall, M.
    Toal, M.
    Hooftman, L.
    Verweij, J.
    Eskens, F. A. L. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
    Simonelli, M.
    Zucali, P. A.
    De Sanctis, R.
    Lorenzi, E.
    De Vincenzo, F.
    Rimassa, L.
    Tronconi, M. C.
    Personeni, N.
    Masci, G.
    Zuradelli, M.
    Perrino, M.
    Bertossi, M.
    Giordano, L.
    Santoro, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
    Garland, LL
    Pegram, M
    Song, S
    Mendelson, D
    Parker, KE
    Martell, RE
    Gordon, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 229S - 229S
  • [34] A phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of an oral antimicrotubular agent, DJ-927 (0), and capecitabine (C) in patients (Pts) with advanced solid tumors.
    Beeram, M
    Saif, MW
    Sarantopoulos, J
    Schwartz, G
    Patnaik, A
    Tolcher, AW
    Cheverton, P
    Kimura, M
    Danna, M
    Takimoto, CH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 144S - 144S
  • [35] A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours.
    Steele, N
    Vidal, L
    Plumb, J
    Attard, G
    Rasmussen, A
    Buhl-Jensen, P
    Brown, R
    Blagden, S
    Evans, J
    de Bono, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 200S - 200S
  • [36] A phase I and pharmacokinetic (PK) study of CX-3543, a protein-rDNA quadruplex inhibitor, in patients (pts) with advanced solid tumors
    Ricart, A. D.
    Papadopoulos, K. P.
    Von Hoff, D. D.
    Lim, J. K. C.
    Marschke, R. F.
    EJC SUPPLEMENTS, 2006, 4 (12): : 111 - 111
  • [37] A phase I clinical, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with advanced solid tumors
    Siu, L. L.
    Burris, H. A., III
    Mileshkin, L. R.
    Camidge, D. R.
    Eckhardt, S. G.
    Lamb, A.
    Chen, E. X.
    Jones, S. F.
    Xu, H.
    Fingert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors
    Zhou, Qing
    Wu, Yi Long
    Yu, Xiyong
    Yang, Jinji
    Wen, Limin
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] A phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in combination with weekly paclitaxel in patients (pts) with advanced solid cancers.
    Patnaik, A
    Mita, AC
    Izbicka, E
    Carrizales, G
    Howes, A
    Troenaru, M
    Tolcher, AW
    Zhang, S
    Berg, K
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 228S - 228S
  • [40] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
    Brunetto, Andre T.
    Ang, Joo Ern
    Lal, Rohit
    Olmos, David
    Molife, L. Rhoda
    Kristeleit, Rebecca
    Parker, Ann
    Casamayor, Isabel
    Olaleye, Muyibat
    Mais, Anna
    Hauns, Bernhard
    Strobel, Vera
    Hentsch, Bernd
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504
12345